Business
Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases
STATEN ISLAND, N.Y., Feb. 7, 2022 /PRNewswire/ -- Publication of study presents: Clinical results of 10 of 10 patients (100%) enrolled met the study's primary
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"STATEN ISLAND, N.Y., Feb. 7, 2022 /PRNewswire/ -- \nPublication of study presents: Clinical results of 10 of 10 patients (100%) enrolled met the study's primary and secondary efficacy endpoints of Clinical Cure at end of treatment and Sustained Clinical Cure of no recurrence of CDI at the 28-day follow-up visit PK data showing low plasma and high fecal concentrations of ibezapolstat Favorable microbiome changes included regrowth of Actinobacteria and Firmicutes phylum species while on treatment Potential beneficial effects on bile acid metabolism while on treatment Currently enrolling Ph2b trial in 12 U.S. sites will compare efficacy of ibezapolstat to vancomycin Ibezapolstat is FDA QIDP and Fast Track Designated for priority reviewAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results of its positive Phase 2a clinical trial have been published in Clinical Infectious Diseases, the official publication of the Infectious Disease Society of America https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac096/6522822?login=true. The senior author of the publication is Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for the microbiome aspects of the trial. \nDr. Garey stated: \"In this publication, we are particularly pleased to present the totality of the ibezapolstat Phase 2a clinical and microbiome data for this promising novel antibiotic which appears to possess key properties of an ideal oral antibiotic for CDI: highly potent against C. difficile; good tolerability; and limited gastrointestinal absorption, resulting in very high fecal concentrations which may reach three orders of magnitude above the MIC for C. difficile.\" He also noted: \"This first-in-class GPSS™ (Gram Positive Selective Spectrum) antimicrobial is a novel DNA polymerase IIIC inhibitor with a unique mechanism of action that targets low G+C content gram-positive bacteria. Ibezapolstat has potent activity as demonstrated by the eradication of C. difficile by day three of treatment. Our data also show it unexpectedly spares other Firmicutes along with the important Actinobacteria phylum necessary for maintaining a healthy...